Market Overview

UPDATE: Stifel Nicolaus Initiates Buy with $72 PT on Mednax; Valuation Attractive

Share:
Related MD
4 Reasons to Stay Away from Mednax Now
Mid-Afternoon Market Update: Dow Surges 200 Points; RLI Shares Drop On Disappointing Results

Stifel Nicolaus initiates its coverage on Mednax (NYSE: MD) with a Buy rating and a $72 price target.

Stifel Nicolaus comments, "We like the company's prospects for internal growth and acquisitions of neonatology and anesthesiology practices, and view the current valuation, at only the 14th percentile of historical forward P/E, as an attractive entry point. …Our Buy rating is based on an improving internal growth rate, an increasing pace of accretive acquisitions, and a current valuation well below the median (since 2004) forward P/E of 15.1x. The current valuation is at only 14th historical percentile. Our target price of $72, equal to a median multiple applied to our forward EPS estimate, implies 20% price appreciation."

MD closed at $60.01 on Monday.

Latest Ratings for MD

DateFirmActionFromTo
Jun 2017Stephens & Co.UpgradesEqual-WeightOverweight
Mar 2017BairdDowngradesOutperformNeutral
Mar 2017JP MorganDowngradesOverweightNeutral

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (MD)

View Comments and Join the Discussion!